On April 5, the U.S. Food and Drug Administration (FDA) revised the Emergency Use Authorization (EUA) for sotrovimab.
Join our family of readers for as little as $5 per month and support local, unbiased journalism.
Already have an account? Log in to continue. Otherwise, follow the link below to join.
Please log in to continue |
TALLAHASSEE — On April 5, the U.S. Food and Drug Administration (FDA) revised the Emergency Use Authorization (EUA) for sotrovimab. The revised EUA does not allow providers to administer this treatment within the United States.
Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody.
This decision leaves the State of Florida with only a single post-exposure monoclonal antibody treatment for COVID-19, bebtelovimab.
The FDA based its decision on the Centers for Disease Control and Prevention’s (CDC’s) Nowcast estimates. Unlike previous revisions on EUAs that stopped treatments at an estimate of 80%, the authorization for sotrovimab removed its use at 50%. According to CDC’s current estimate, 40% of COVID-19 cases in Florida would still benefit from this life-saving treatment.
As is tradition at the FDA, this change comes after a single live virus pre-print study with no clinical data. Florida disagrees with decisions on preventions and treatments without being provided any supporting clinical data.
For more information,contact the FDA at 1-888-463-6332.
To find locations with prevention and treatment options, visit the Florida Department of Health treatment locator at: floridahealthcovid19.gov/
About the Florida Department of Health
Follow the Florida Department of Health on Facebook, Instagram and Twitter at @HealthyFla. For more information, please visit www.FloridaHealth.gov.
